Docality.com Logo
 
Dr. Eugene  Yang  Md image

Dr. Eugene Yang Md

1700 116Th Ave Ne
Bellevue WA 98004
425 467-7777
Medical School: University Of Pennsylvania School Of Medicine - 1997
Accepts Medicare: No
Participates In eRX: Yes
Participates In PQRS: Yes
Participates In EHR: Yes
License #: MD00047214
NPI: 1184654782
Taxonomy Codes:
207RC0000X 207UN0901X

Request Appointment Information

Awards & Recognitions

About Us

Practice Philosophy

Conditions

Dr. Eugene Yang is associated with these group practices

Procedure Pricing

HCPCS Code Description Average Price Average Price
Allowed By Medicare
HCPCS Code:99205 Description:Office/outpatient visit new Average Price:$439.50 Average Price Allowed
By Medicare:
$210.80
HCPCS Code:99215 Description:Office/outpatient visit est Average Price:$308.30 Average Price Allowed
By Medicare:
$148.74
HCPCS Code:93350 Description:Stress tte only Average Price:$226.80 Average Price Allowed
By Medicare:
$76.20
HCPCS Code:93306 Description:Tte w/doppler complete Average Price:$201.40 Average Price Allowed
By Medicare:
$67.62
HCPCS Code:99214 Description:Office/outpatient visit est Average Price:$229.50 Average Price Allowed
By Medicare:
$111.06
HCPCS Code:93227 Description:Ecg monit/reprt up to 48 hrs Average Price:$82.70 Average Price Allowed
By Medicare:
$27.90
HCPCS Code:93308 Description:Tte f-up or lmtd Average Price:$80.60 Average Price Allowed
By Medicare:
$27.09
HCPCS Code:93016 Description:Cardiovascular stress test Average Price:$68.90 Average Price Allowed
By Medicare:
$23.17
HCPCS Code:93000 Description:Electrocardiogram complete Average Price:$59.40 Average Price Allowed
By Medicare:
$20.73
HCPCS Code:93018 Description:Cardiovascular stress test Average Price:$46.60 Average Price Allowed
By Medicare:
$15.67
HCPCS Code:93325 Description:Doppler color flow add-on Average Price:$25.00 Average Price Allowed
By Medicare:
$3.87
HCPCS Code:93010 Description:Electrocardiogram report Average Price:$26.50 Average Price Allowed
By Medicare:
$8.87
HCPCS Code:93321 Description:Doppler echo exam heart Average Price:$23.30 Average Price Allowed
By Medicare:
$7.79

HCPCS Code Definitions

93010
Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only
93000
Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report
93227
External electrocardiographic recording up to 48 hours by continuous rhythm recording and storage; review and interpretation by a physician or other qualified health care professional
93018
Cardiovascular stress test using maximal or submaximal treadmill or bicycle exercise, continuous electrocardiographic monitoring, and/or pharmacological stress; interpretation and report only
93306
Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography
93016
Cardiovascular stress test using maximal or submaximal treadmill or bicycle exercise, continuous electrocardiographic monitoring, and/or pharmacological stress; supervision only, without interpretation and report
93308
Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, follow-up or limited study
93350
Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, during rest and cardiovascular stress test using treadmill, bicycle exercise and/or pharmacologically induced stress, with interpretation and report
93321
Doppler echocardiography, pulsed wave and/or continuous wave with spectral display (List separately in addition to codes for echocardiographic imaging); follow-up or limited study (List separately in addition to codes for echocardiographic imaging)
93325
Doppler echocardiography color flow velocity mapping (List separately in addition to codes for echocardiography)
99205
Office or other outpatient visit for the evaluation and management of a new patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; Medical decision making of high complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Typically, 60 minutes are spent face-to-face with the patient and/or family.
99214
Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: A detailed history; A detailed examination; Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Typically, 25 minutes are spent face-to-face with the patient and/or family.
99215
Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: A comprehensive history; A comprehensive examination; Medical decision making of high complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Typically, 40 minutes are spent face-to-face with the patient and/or family.

Medical Malpractice Cases

None Found

Medical Board Sanctions

None Found

Referrals

NPI
Doctor Name
Specialty
Count
1841357381
Internal Medicine
2,389
1790861458
Family Practice
2,261
1538244355
Family Practice
2,161
1861572844
Family Practice
1,712
1962587766
Internal Medicine
1,405
1386729119
Family Practice
864
1831171586
Cardiac Electrophysiology
597
1790864452
Family Practice
491
1225250194
Internal Medicine
490
1225113046
Cardiovascular Disease (Cardiology)
373
*These referrals represent the top 10 that Dr. Yang has made to other doctors

Publications

PCSK9 Inhibitors- Are we on the verge of a breakthrough? - Clinical pharmacology and therapeutics
Statins are first-line therapy for lowering cholesterol and reducing cardiovascular events. A significant need for new lipid-modifying therapies remains for patients unable to tolerate statins or achieve guideline-based cholesterol targets. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a key regulator of LDL receptor recycling. Gain-of-function PCSK9 mutations are associated with high LDL cholesterol (LDL-C) levels and increased risk of coronary artery disease while loss-of-function variants result in low LDL-C and decreased risk of cardiovascular events. PCSK9 monoclonal antibody inhibitors have been developed and lower LDL-C levels up to 70% in clinical trials. These inhibitors are well tolerated with low serious adverse event rates. Phase III clinical outcome trials with these agents are ongoing and will determine their efficacy in reducing cardiovascular events and address long-term safety concerns. This article is protected by copyright. All rights reserved.© 2015 American Society for Clinical Pharmacology and Therapeutics.
Current antiplatelet agents: place in therapy and role of genetic testing. - Journal of thrombosis and thrombolysis
Antiplatelet therapies play a central role in reducing the risk of cardiovascular events such as myocardial infarction and stroke. While aspirin, a cyclo-oxygenase-1 inhibitor has been the cornerstone of antithrombotic treatment for several decades, P2Y12 receptor inhibitors cangrelor, clopidogrel, prasugrel, and ticagrelor and protease-activated receptor-1 antagonist vorapaxar, have emerged as additional therapies to reduce the risk of recurrent cardiovascular events in high-risk patients. Recent clinical trials evaluating the role of these agents and major society guideline updates for use of antiplatelet therapies for secondary prevention of cardiovascular events will be examined. The latest studies regarding the appropriate duration of dual antiplatelet therapy after percutaneous coronary intervention will be presented. The current state of genetic and platelet function testing will be reviewed.
Spinal cord ischemia secondary to hypovolemic shock. - Asian spine journal
A 44-year-old male presented with symptoms of spinal cord compression secondary to metastatic prostate cancer. An urgent decompression at the cervical-thoracic region was performed, and there were no complications intraoperatively. Three hours postoperatively, the patient developed acute bilateral lower-limb paralysis (motor grade 0). Clinically, he was in class 3 hypovolemic shock. An urgent magnetic resonance imaging (MRI) was performed, showing no epidural hematoma. He was managed aggressively with medical therapy to improve his spinal cord perfusion. The patient improved significantly, and after one week, he was able to regain most of his motor functions. Although not commonly reported, spinal cord ischemia post-surgery should be recognized early, especially in the presence of hypovolemic shock. MRI should be performed to exclude other potential causes of compression. Spinal cord ischemia needs to be managed aggressively with medical treatment to improve spinal cord perfusion. The prognosis depends on the severity of deficits, and is usually favorable.
Resolution of right-sided heart failure symptoms after resection of a primary ovarian carcinoid tumor. - Texas Heart Institute journal / from the Texas Heart Institute of St. Luke's Episcopal Hospital, Texas Children's Hospital
Carcinoid tumors are rare neuroendocrine malignancies that typically originate from the gastrointestinal tract. Patients who are diagnosed with carcinoid heart disease generally have poor prognoses because of advanced metastases during staging and few therapeutic options. We present the case of a 61-year-old woman with right-sided heart failure, secondary to carcinoid heart disease caused by a primary ovarian carcinoid tumor. After undergoing surgical resection of the left ovary and fallopian tube, the patient experienced complete resolution of her heart failure symptoms. In addition to the patient's case, we discuss the diagnosis, nature, and treatment of this rare condition.
Selective JAK inhibitors. - Future medicinal chemistry
Consisting of four members, JAK1, JAK2, JAK3 and TYK2, the JAK kinases have emerged as important targets for proliferative and immune-inflammatory disorders. Recent progress in the discovery of selective inhibitors has been significant, with selective compounds now reported for each isoform. This article summarizes the current state-of-the-art with a discussion of the most recently described selective compounds. X-ray co-crystal structures reveal the molecular reasons for the observed biochemical selectivity. A concluding analysis of JAK inhibitors in the clinic highlights increased clinical trial activity and diversity of indications. Selective JAK inhibitors, as single agents or in combination regimens, have a very promising future in the treatment of oncology, immune and inflammatory diseases.
A clinician's perspective: novel oral anticoagulants to reduce the risk of stroke in nonvalvular atrial fibrillation--full speed ahead or proceed with caution? - Vascular health and risk management
Over the past few years, three novel oral anticoagulants, dabigatran, rivaroxaban, and apixaban, have been approved in the USA and Europe to reduce the risk of stroke or systemic embolism in patients with nonvalvular atrial fibrillation, and the results of a Phase III trial for a fourth novel oral anticoagulant, edoxaban, have recently been published. The aim of this review is to examine this indication from a clinician's perspective, highlighting efficacy and safety results from the major trials with these novel oral agents. Clinical issues regarding bleeding, monitoring, and reversal are discussed, along with requirements to consider when interrupting treatment with a novel oral anticoagulant for the purpose of transitioning to another anticoagulant and prior to cardioversion, ablation, percutaneous coronary intervention, or emergency surgery. The cost-effectiveness of each of the approved novel oral anticoagulants is reviewed, and the author provides recommendations for selecting appropriate patients for these agents.
In vivo bioluminescence imaging of inducible nitric oxide synthase gene expression in vascular inflammation. - Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging
Inflammation plays a critical role in atherosclerosis and is associated with upregulation of inducible nitric oxide synthase (iNOS). We studied bioluminescence imaging (BLI) to track iNOS gene expression in a murine model of vascular inflammation.Macrophage-rich vascular lesions were induced by carotid ligation plus high-fat diet and streptozotocin-induced diabetes in 18 iNOS-luc reporter mice. In vivo iNOS expression was imaged serially by BLI over 14 days, followed by in situ BLI and histology.BLI signal from ligated carotids increased over 14 days (9.7 ± 4.4 × 10(3 ) vs. 4.4 ± 1.7 × 10(3) photons/s/cm(2)/sr at baseline, p < 0.001 vs. baseline, p < 0.05 vs. sham controls). Histology confirmed substantial macrophage infiltration, with iNOS and luciferase expression, only in ligated left carotid arteries and not controls.BLI allows in vivo detection of iNOS expression in murine carotid lesions and may provide a valuable approach for monitoring vascular gene expression and inflammation in small animal models.
Relationship among pulmonary function, bronchial hyperresponsiveness, and atopy in children with clinically stable asthma. - Lung
Pulmonary function testing plays a key role in the diagnosis and management of asthma in children. However, the literature does not clearly show whether children with clinically stable asthma have significantly reduced lung function when compared with normal children. We compared the lung function of 242 clinically stable asthmatic children who were initially diagnosed with mild intermittent or mild persistent asthma with the lung function of 100 nonasthmatic controls. The lung function was assessed using FEV1, FEV1/FVC, FEF25-75 and PEF. In addition, we measured bronchial hyperresponsiveness (BHR) using the provocation concentration of methacholine needed to produce a 20% fall in FEV1. All measures of pulmonary function were significantly decreased in the children with asthma. Pulmonary function was not influenced by atopy, serum IgE, or total eosinophil count (TEC). However, the likelihood ratio for trends revealed a significant association between our pulmonary parameters and the degree of BHR. Children with mild-to-severe BHR had greatly decreased lung function compared with those with normal BHR, the control group. In addition, a direct correlation was found between PC20 and our pulmonary parameters in asthmatic children. However, only atopic children with asthma had a significant correlation between PC20 and TEC. We found children with clinically stable asthma to have pulmonary obstruction, which associated strongly with their degree of BHR.
Pathway analysis of coronary atherosclerosis. - Physiological genomics
Large-scale gene expression studies provide significant insight into genes differentially regulated in disease processes such as cancer. However, these investigations offer limited understanding of multisystem, multicellular diseases such as atherosclerosis. A systems biology approach that accounts for gene interactions, incorporates nontranscriptionally regulated genes, and integrates prior knowledge offers many advantages. We performed a comprehensive gene level assessment of coronary atherosclerosis using 51 coronary artery segments isolated from the explanted hearts of 22 cardiac transplant patients. After histological grading of vascular segments according to American Heart Association guidelines, isolated RNA was hybridized onto a customized 22-K oligonucleotide microarray, and significance analysis of microarrays and gene ontology analyses were performed to identify significant gene expression profiles. Our studies revealed that loss of differentiated smooth muscle cell gene expression is the primary expression signature of disease progression in atherosclerosis. Furthermore, we provide insight into the severe form of coronary artery disease associated with diabetes, reporting an overabundance of immune and inflammatory signals in diabetics. We present a novel approach to pathway development based on connectivity, determined by language parsing of the published literature, and ranking, determined by the significance of differentially regulated genes in the network. In doing this, we identify highly connected "nexus" genes that are attractive candidates for therapeutic targeting and followup studies. Our use of pathway techniques to study atherosclerosis as an integrated network of gene interactions expands on traditional microarray analysis methods and emphasizes the significant advantages of a systems-based approach to analyzing complex disease.
Molecular cloning of nonsecreted endothelial cell-derived lipase isoforms. - Genomics
To expand our knowledge of factors involved in lipid metabolism in the blood vessel wall, we have cloned unique molecular isoforms of endothelial cell-derived lipase (EDL) (HGMW-approved symbol/LIPG). One isoform encoded a truncated protein (EDL2a) lacking the first 80 amino acid residues of the previously characterized EDL1a isoform, including the signal peptide. A similar second clone (EDL2b) was identified that lacked not only the first 80 amino acids, but also a 74-amino-acid region that encodes a portion of the lid domain. RT-PCR analysis confirmed expression of EDL2a/2b isoforms in several human tissues and cultured cells, including endothelial cells. Western blot and immunofluorescence studies using stable transfectants revealed that EDL2a and EDL2b were localized in the cytosol, while, EDL1a was secreted into the culture medium. Cell extracts of EDL2a/2b transfectants did not have triglyceride or phospholipase activity. Thus endothelial cells express three EDL isoforms, two of which remain intracellular and do not function as lipases.

Map & Directions

1700 116Th Ave Ne Bellevue, WA 98004
View Directions In Google Maps

Nearby Doctors

1135 116Th Ave Ne Suite 110
Bellevue, WA 98004
425 893-3100
1621 114Th Ave Se Suite 221
Bellevue, WA 98004
425 551-1560
10687 Ne 2Nd St
Bellevue, WA 98004
425 550-0444
2820 Northup Way Suite 250
Bellevue, WA 98004
206 183-3370
11201 Se 8Th St Suite #105
Bellevue, WA 98004
425 540-0255
1400 116Th Ave Ne
Bellevue, WA 98004
425 741-1538
11201 Se 8Th St Suite 105
Bellevue, WA 98004
425 540-0255
1611 116Th Ave Ne Suite 128
Bellevue, WA 98004
206 196-6565
3039 110Th Ave Se
Bellevue, WA 98004
425 555-5081
1900 116Th Ave Ne
Bellevue, WA 98004
425 530-0404